The Latest Cardiac and Vascular News
Topline Results from SEQUOIA-HCM Announced in December Showed Statistically Significant and Clinically Meaningful Increase in Primary Efficacy Endpoint and Improvements in All Secondary Endpoints Company Plans to Submit New Drug Application for Aficamten to FDA in Q3 2024 and Marketing […]
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its sixth annual Communications Grant Program, intended to support increased capacity in communications, awareness building and community engagement. Five grants in […]
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data at CMR 2024 demonstrating favorable effects on cardiac structure, function and fibrosis related to treatment with aficamten in FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), the open label extension clinical trial […]
Statistically Significant and Clinically Meaningful Increase in Primary Efficacy Endpoint at 24 Weeks of Treatment; Improvement Consistent Across All Prespecified Subgroups Statistically Significant and Clinically Meaningful Improvements in All Secondary Endpoints No Instances of Treatment Interruptions Due to Low LVEF […]
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2023 it granted stock options to purchase an aggregate of 25,350 shares of common stock to two new employees, whose […]
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 31, 2023 it granted stock options to purchase an aggregate of 22,350 shares of common stock to five new employees, whose […]
On Track for Topline Results from SEQUOIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Obstructive HCM, in Late December Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten, Show Sustained Improvements in Clinical Efficacy Endpoints and No […]
New Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten, Show Sustained Improvements in Clinical Efficacy Endpoints and No Treatment Interruptions for Low Ejection Fraction Commercial Readiness Activities Leverage Insights from Market Research to Inform Market Segmentation and Patient-Centric […]
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM), a Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), is open to […]
SOUTH SAN FRANCISCO, Calif., July 05, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 30, 2023 it granted stock options to purchase an aggregate of 77,450 shares of common stock to 5 new employees, whose […]
